The focus of Affibody AB is to develop next generation biotherapeutics based on the proprietary technology platforms: Affibody® molecule and Albumod™.
More information at [www.affibody.com](http://www.affibody.com).

The In Vitro Pharmacology (IVP) group at Affibody AB is responsible for characterization of Affibody® molecules including analysis of immunogenicity and Technical Office group is responsible for improvement of the Affibody® platform. During the fall of 2021, the two departments are together planning a 30p Exam work with the preliminary title:

**Drug development and Immunogenicity**

**Background:**
Affibody AB is a biotherapeutic company with several Affibody® molecules under development and in clinical studies. Simultaneously, the company continuously strives to improve the characteristics of the Affibody® molecules. When changing the amino acid composition of the molecule, the properties of the molecule may change leading to increased immunogenicity. The aim of the proposed 30p Exam work is to assess the immunogenic propensity after mutation of certain amino acids in the scaffold of the Affibody® molecule.

**Performance:**
The aim of the exam work is to analyze the binding ability of Affibody® molecules with or without mutations. The work includes:

- Production of Affibody® molecules in *E. coli* followed by purification with affinity chromatography.
- Purity and function analysis of purified Affibody® molecules (SDS-PAGE and Biacore).
- Cleavage of antibodies with enzymes to produce Fab or alternatively (Fab)2-fragments.
- Comparative analysis of Affibody® molecules and Fab alternatively (Fab)2-fragments with ELISA or alternatively Biacore.

**Supervisors**
Ingmarie Höidén-Guthenberg, [ingmarieh@affibody.se](mailto:ingmarieh@affibody.se), Joakim Nilsson, [joakim.nilsson@affibody.se](mailto:joakim.nilsson@affibody.se), and Malin Ryner, [malin.ryner@affibody.se](mailto:malin.ryner@affibody.se)

**Address**
Affibody AB, Scheeles väg 2, 171 65 Solna.

**Interested?**
If you are interested, please send an e-mail with CV and a personal letter not later than 2021-06-07.